Research programme - cyclin dependent kinase 2 modulators - Chongqing Fochon Pharmaceutical
Latest Information Update: 27 Jan 2023
Price :
$50 *
At a glance
- Originator Chongqing Fochon Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action Cyclin-dependent kinase 2 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 29 Nov 2022 Early research in Cancer in China (unspecified route), prior to November 2022 (Chongqing Fochon Pharmaceutical pipeline, November 2022)